Australia’s first and only large-scale manufacturer of customised 3D printed medical and healthcare devices was founded in Melbourne in 2016. As an industry first-mover, the company faced the difficulties associated with navigating Australia’s complex regulatory environment.

Civic has provided media relations, industry engagement and regulatory affairs support to the company since its opening, regularly securing speaking engagements at industry events and appearances in industry and national media.

Our strategic engagement and communications advice and guidance helped the company secure regulatory approval for a range of devices, including a 3D-printed swab which was deployed as part of a COVID testing kit.

An Australian-listed global biopharmaceutical company developing and commercialising treatments for patients with genetic, metabolic and life-threatening disorders turned to Civic for better positioning in local and global markets.

Civic developed and delivered a program built around raising awareness of key regulatory milestones, such as FDA and other global market approvals, and the commercialisation of life-saving drugs.

With a booming share price a reflection of increasing market awareness, Civic focused on communicating the company’s plans for future growth and repositioning senior management in the media and the market, resulting in positive coverage in the lead up to the company’s AGM.